From inflammation to remission: The promising role of jun kinase inhibitors in endometriosis
Stephen Palmer from Baylor College of Medicine presented his speech at the Annual International Medical Conference of the Endometriosis Foundation of America held in New York on April 1-2, 2023. Dr. Palmer began his talk with a philosophy and a personal statement “Endometriosis is…
Key Points Lay SummaryInflammatory and genetical background of endometriosis may yield new therapeutic approaches
Elisa Giacomini and colleagues from medical centers in Milan, Italy have published their review manuscript on the inflammatory and genetical pathogenetic background of endometriosis in a recent issue of “International Journal of Molecular Sciences”, suggesting also new therapeutic approaches. The inflammatory…
Key Points Lay SummaryA pilot study for Endometriosis Potential biomarkers
Endometriosis is one of the most common female health disorders typically causing dysmenorrhea, dyspareunia, and pelvic pain, and may contribute to infertility. It is necessary to identify potential molecular biomarkers for diagnosis and regulatory factors behind the disease. The study…
Key Points Lay SummaryControl on endometriosis progression by a "tyrosine kinase inhibitor"
B cells, which are important players of the immune system, are increased in the blood and peritoneal cavity of endometriosis patients. Activation of B cells and the presence of anti-endometrial autoantibodies have been also been described in women with endometriosis,…
Key Points Lay SummaryMitogen-Activated Protein Kinase p38 modulates Inflammation in Endometriosis
The p38 mitogen-activated protein kinase (MAPK) is a serine/threonine kinase, which transduces signals within the cell in response to various environmental stimuli. In doing so, it mediates intracellular signaling of cytokine production, cell proliferation, and apoptosis amongst many other cellular…
Key Points Lay Summary